clinical trial · NCT06502990
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma·phase3·recruiting·n = 15
Generalized LipodystrophyMetreleptin
brief summary
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia
started
May 23, 2025
primary completion
Sep 30, 2026
completion
Sep 30, 2026
last updated
Jan 20, 2026
official title
Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol